Full Press Release Details
BridgeBio Pharma's Origin Biosciences Announces FDA Approval Of NULIBRY (fosdenopterin) For The Treatment Of Patients With MoCD Type A.
BBIO
BridgeBio Pharma's Origin Biosciences Announces FDA Approval Of NULIBRY (fosdenopterin) For The Treatment Of Patients With MoCD Type A
Key Takeaway: BridgeBio Pharma's Origin Biosciences Announces FDA Approval Of NULIBRY (fosdenopterin) For The Treatment Of Patients With MoCD Type A